Rakuten Medical



Amy Haseley Thorne, Ph.D.

Chief Scientific Officer,
Rakuten Medical, Inc.

As Chief Scientific Officer at Rakuten Medical, Amy leads the company's research initiatives to advance new treatments in the pre-clinical phase based on Rakuten Medical's proprietary Alluminox® platform.

Amy brings extensive expertise in tumor microenvironment dynamics, therapeutic resistance, and the antitumor activity of novel therapies. Since joining Rakuten Medical in 2019, she has played a pivotal role in translating pre-clinical discoveries into clinical development across the company's global pipeline, including key assets ASP-1929, RM-1995, and RM-0256. She also leads the biomarker team, which supports clinical trial design and execution and leverages AI-driven technologies for data quantification and analysis. Known for her results-driven, big-picture approach, Amy has successfully built and led high-performing, interdisciplinary teams, fostering collaboration and generating high-quality data.

Prior to joining Rakuten Medical, Amy led the immuno-oncology research team at Inovio Pharmaceuticals, driving pre-clinical development of DNA-encoded cancer vaccines, monoclonal antibodies, and bispecific T cell engagers. She has a proven track record of success, demonstrated by peer-reviewed publications in high-impact journals and international presentations to the scientific community.

Amy received her Bachelor of Science in Biology and Ph.D. in Neuroscience from The Ohio State University and completed a postdoctoral fellowship at the Ludwig Institute for Cancer Research at the University of California, San Diego.